Condition

Clinical trials for Overweight

Active public studies that list Overweight as a condition.

205active studies

93recruiting now

47countries represented

783largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowNot applicable

Impact of Overweight, Obesity, and Lifestyle Changes on Work Performance and Well-Being in Medical Residents

Obesity, OverweightCondition

Obesity and Overweight Status, No Intervention (Observational Assessment)Treatment

Italy1 locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSponsor

Updated 2026-09-08 · NCT07677800See eligibility →

Recruiting nowPhase 3

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Diabetes Mellitus, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Brazil74 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07533175See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 3

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, Placebo cagrilintideTreatment

Greece, Hungary36 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07745504See eligibility →

Recruiting nowPhase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC0721-8060, SemaglutideTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07767175See eligibility →

Recruiting nowNot applicable

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

Overweight, ObesityCondition

Standard Diet, Ketogenic DietTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-04 · NCT06044935See eligibility →

Recruiting nowPhase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Atherosclerotic Cardiovascular Disease, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia783 locations

AmgenSponsor

Updated 2026-09-03 · NCT07037433See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 1

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Overweight, ObesityCondition

RO7795081, PlaceboTreatment

Netherlands1 locations

Hoffmann-La RocheSponsor

Updated 2026-09-03 · NCT06982131See eligibility →

Recruiting nowPhase 1

A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo

Overweight, ObesityCondition

NNC0487-0111, PlaceboTreatment

Denmark, Netherlands2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-02 · NCT07757087See eligibility →

Recruiting nowPhase 2

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

Overweight, Overweight and ObesityCondition

Counseling, Text MessagesTreatment

United States1 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-09-02 · NCT05770570See eligibility →

Recruiting nowNot applicable

Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure

Hypertension (Without Type 2 Diabetes Mellitus), High Blood PressureCondition

Wild Blueberry, PlaceboTreatment

United States1 locations

Georgia State UniversitySponsor

Updated 2026-09-02 · NCT06735599See eligibility →

Recruiting nowNot applicable

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes

Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), FemaleCondition

Wild Blueberry, PlaceboTreatment

United States1 locations

Georgia State UniversitySponsor

Updated 2026-09-02 · NCT06735651See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 1

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Obesity, OverweightCondition

LY4174794, LY4174794Treatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-09-01 · NCT07654972See eligibility →

Recruiting nowNot applicable

HealthyTogether: RCT of a Dyadic Weight Management Intervention

Obesity, OverweightCondition

HealthyTogetherTreatment

United States2 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-09-01 · NCT06619041See eligibility →

Recruiting nowPhase 2

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

Healthy Volunteers, OverweightCondition

Sucralose, PlaceboTreatment

United States1 locations

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Sponsor

Updated 2026-09-01 · NCT03407079See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 1

A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant

Overweight, ObesityCondition

UBT251, Oral contraceptiveTreatment

Canada1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07710729See eligibility →

Recruiting nowPhase 3

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Belgium, Brazil117 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672549See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Argentina, Australia162 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07321886See eligibility →

Recruiting nowPhase 1

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Singapore, United States2 locations

Eli Lilly and CompanySponsor

Updated 2026-08-20 · NCT07738614See eligibility →

Recruiting nowPhase 3

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Overweight, ObesityCondition

Semaglutide, PlaceboTreatment

Belgium, Bulgaria62 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07770841See eligibility →

Recruiting nowPhase 1

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

Obesity, OverweightCondition

UBT251, Cocktail (Warfarin/Caffeine/Midazolam)Treatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07710768See eligibility →

Recruiting nowPhase 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, Bulgaria81 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT07509307See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Czechia, Germany136 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743450See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Canada, Czechia120 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743463See eligibility →

Recruiting nowPhase 3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Obesity, OverweightCondition

Enicepatide, PlaceboTreatment

China18 locations

Hoffmann-La RocheSponsor

Updated 2026-08-13 · NCT07670416See eligibility →

Recruiting nowNot applicable

The PreEclampsia Postpartum Prevention Trial

Preeclampsia, Postpartum PeriodCondition

Bundle InterventionTreatment

Sweden2 locations

Karolinska InstitutetSponsor

Updated 2026-08-12 · NCT07199283See eligibility →

Recruiting nowPhase 1

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

Obesity, OverweightCondition

VRB-103, PlaceboTreatment

Australia1 locations

Verdiva Bio Dev LimitedSponsor

Updated 2026-08-11 · NCT07628127See eligibility →

Recruiting nowNot applicable

Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy

Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder)Condition

NutriSteppe Digital Dietary InterventionTreatment

Kazakhstan1 locations

Kazakh Academy of NutritionSponsor

Updated 2026-08-11 · NCT07728669See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 1

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

Obesity, OverweightCondition

NNC0113-5840, PlaceboTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07566390See eligibility →

Recruiting nowNot applicable

Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change

Overweight, ObesityCondition

Low-carbohydrate Diet, Low-fat DietTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-07-31 · NCT06325722See eligibility →

Recruiting nowPhase 1

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

Healthy, ObesityCondition

Formulation A, Formulation B6Treatment

United Kingdom1 locations

Boehringer IngelheimSponsor

Updated 2026-07-30 · NCT07407348See eligibility →

Recruiting nowPhase 1

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC6989-0001, Placebo (NNC6989-0001)Treatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-07-29 · NCT07437079See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Obesity, OverweightCondition

KAI-7535, PlaceboTreatment

Australia, United States36 locations

KaileraSponsor

Updated 2026-07-28 · NCT07497880See eligibility →

Recruiting nowNot applicable

Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies

Food Addiction Tendency, ObesityCondition

SemaglutideTreatment

South Korea1 locations

Seoul National University HospitalSponsor

Updated 2026-07-28 · NCT07732426See eligibility →

Recruiting nowPhase 1

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Germany, Sweden2 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT07665879See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowPhase 1

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

Obesity, OverweightCondition

Cagrilintide D, Cagrilintide B and placebo semaglutide ITreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-26 · NCT07597018See eligibility →

Recruiting nowPhase 1

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Obesity, OverweightCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

United States11 locations

Novo Nordisk A/SSponsor

Updated 2026-06-25 · NCT07607587See eligibility →

Recruiting nowPhase 2

Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients

Overweight, ObesityCondition

KDS2010, KDS2010Treatment

South Korea3 locations

NeuroBiogen Co., LtdSponsor

Updated 2026-06-24 · NCT07009171See eligibility →

Recruiting nowPhase 1

A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity

Type 1 Diabetes (T1D), OverweightCondition

NNC0497-0040, PlaceboTreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-04 · NCT07578584See eligibility →

Recruiting nowNot applicable

The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults

Overweight, Fatty Liver DiseaseCondition

Placebo, orange peel fermentationTreatment

Taiwan1 locations

TCI Co., Ltd.Sponsor

Updated 2026-05-29 · NCT04496895See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Overweight, ObesityCondition

IBI362, PlaceboTreatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2026-05-27 · NCT07469800See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related conditions

Obesity1,102 Obesity & Overweight220 Overweight and Obesity130 Type 2 Diabetes108 Hypertension107

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.